L
35.00
3.52 (11.18%)
| 前收盘价格 | 31.48 |
| 收盘价格 | 32.26 |
| 成交量 | 4,166,892 |
| 平均成交量 (3个月) | 1,617,176 |
| 市值 | 6,441,014,784 |
| 预期市盈率 (P/E Forward) | 1.00 |
| 价格/销量 (P/S) | 9.67 |
| 股市价格/股市净资产 (P/B) | 5.85 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 - 11 Aug 2025 |
| 营业毛利率 | -28.22% |
| 营业利益率 (TTM) | -40.19% |
| 稀释每股收益 (EPS TTM) | -0.960 |
| 季度收入增长率 (YOY) | 134.70% |
| 总债务/股东权益 (D/E MRQ) | 33.69% |
| 流动比率 (MRQ) | 4.62 |
| 营业现金流 (OCF TTM) | -144.03 M |
| 杠杆自由现金流 (LFCF TTM) | -38.58 M |
| 资产报酬率 (ROA TTM) | -10.84% |
| 股东权益报酬率 (ROE TTM) | -15.45% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Legend Biotech Corporation | 看跌 | 看跌 |
AIStockmoo 评分
1.9
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.88 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 1.33% |
| 机构持股比例 | 55.58% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 84.00 (RBC Capital, 140.00%) | 购买 |
| 中 | 75.00 (114.29%) | |
| 低 | 55.00 (Cantor Fitzgerald, 57.14%) | 购买 |
| 平均值 | 73.00 (108.57%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 32.30 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 55.00 (57.14%) | 购买 | 27.80 |
| Truist Securities | 14 May 2025 | 71.00 (102.86%) | 购买 | 27.80 |
| RBC Capital | 22 Apr 2025 | 84.00 (140.00%) | 购买 | 34.48 |
| HC Wainwright & Co. | 16 Apr 2025 | 75.00 (114.29%) | 购买 | 33.46 |
| 08 Apr 2025 | 75.00 (114.29%) | 购买 | 30.77 | |
| Morgan Stanley | 17 Mar 2025 | 80.00 (128.57%) | 购买 | 37.94 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合